Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21640024 | 0.81 | CYP3A4 (0.44) | OPRM1OPRD1OPRK1OPRL1CYP3A4 | |
| SCHEMBL4578709 | 0.80 | CYP3A4 (0.49) | OPRM1OPRD1OPRK1OPRL1CYP3A4 | |
| SCHEMBL4148742 | 0.75 | KMT2A (0.59) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL17726230 | 0.75 | KMT2A (0.45) | OPRM1OPRD1OPRK1OPRL1KMT2A | |
| SCHEMBL3315239 | 0.74 | CYP3A4 (0.47) | OPRM1OPRD1OPRK1OPRL1CYP3A4 | |
| SCHEMBL69083 | 0.74 | OPRM1 (0.56) | OPRM1OPRD1OPRK1OPRL1CYP3A4 | |
| SCHEMBL7391113 | 0.73 | CYP3A4 (0.44) | OPRM1OPRD1OPRK1OPRL1CYP3A4 | |
| SCHEMBL30713496 | 0.73 | CYP3A4 (0.40) | OPRD1CYP3A4CYP2D6HIF1ACYP2C9 | |
| SCHEMBL27827700 | 0.73 | CYP3A4 (0.43) | OPRM1OPRD1OPRK1OPRL1CYP3A4 | |
| SCHEMBL14684169 | 0.73 | CYP3A4 (0.44) | OPRM1OPRD1OPRK1OPRL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| CN-101605540-A | Methods of using MEK inhibitors | EXELIXIS INC (US) | 2009-12-16 | — | — | CN | disclosed |
| EP-2101759-A1 | METHODS OF USING MEK INHIBITORS | Exelixis, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | OPRM1 2870/4885OPRD1 3188/4885OPRK1 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.